# GRI Bio, Inc.: overview

GRI · Nasdaq · CIK 1824293 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gri.md) · [Financials](/companies/gri/financials.md) · [Filings](/companies/gri/filings.md) · [Insiders](/companies/gri/insiders.md)

Latest reported revenue: [$0](/filings/0001824293-22-000034.md) for Q1 FY2022, three months to 2022-03-31, from the 10-Q filed May 9, 2022 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001824293-22-000034).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(11.42)](/filings/0001824293-25-000151.md) | not reported | [(162.30)](/filings/0001824293-26-000044.md) | [(36.72)](/filings/0001824293-26-000055.md) | [(1.28)](/filings/0001824293-25-000151.md) | not reported | [(1.61)](/filings/0001824293-26-000044.md) | [(0.91)](/filings/0001824293-26-000055.md) |
| Free cash flow | $k | [(2,268) d](/filings/0001824293-25-000151.md) | [(1,999) d](/filings/0001824293-26-000033.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001824293-22-000004.md) | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.42)](/filings/0001824293-23-000016.md) | [(24.95)](/filings/0001824293-24-000033.md) | [(5018.09)](/filings/0001824293-25-000050.md) | [(1545.55)](/filings/0001824293-26-000033.md) | [(121.80)](/filings/0001824293-26-000033.md) |
| Free cash flow | $m | [(8.3)](/filings/0001824293-23-000016.md) | [(1.1)](/filings/0001824293-24-000033.md) | [(9.0)](/filings/0001824293-25-000050.md) | [(8.6)](/filings/0001824293-26-000033.md) | [(10.2)](/filings/0001824293-26-000033.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gri/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $37.8k | 21,368 |  | New +21,368 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $24.5k | 13,869 |  | Reduced −4,569 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $23.7k | 13,376 |  | New +13,376 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $15.5k | 8,737 |  | New +8,737 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $8.7k | 4,920 |  | Reduced −3,802 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.3k | 2,434 |  | Added +1,374 |
| [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $147 | 83 |  | New +83 |
| [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $50 | 28,784 |  | New +28,784 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12 | 7 |  | Unchanged |
| [DANSKE BANK A/S](/funds/800177.md) | 2026-06-30 | $4 | 2 |  | Unchanged |

## Recent filings

[All 399 filings](/companies/gri/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-28 | 16:43 ET | [DEF 14A](/filings/0001824293-26-000060.md) | Proxy statement, period 2026-11-04 | 0001824293-26-000060 |
| 2026-09-08 | 08:16 ET | [8-K](/filings/0001824293-26-000057.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001824293-26-000057 |
| 2026-08-14 | 07:44 ET | [10-Q](/filings/0001824293-26-000055.md) | Quarterly report, period 2026-06-30 | 0001824293-26-000055 |
| 2026-06-18 | 16:50 ET | [8-K](/filings/0001824293-26-000050.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001824293-26-000050 |
| 2026-05-14 | 08:36 ET | [8-K](/filings/0001824293-26-000046.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001824293-26-000046 |
| 2026-05-13 | 16:16 ET | [10-Q](/filings/0001824293-26-000044.md) | Quarterly report, period 2026-03-31 | 0001824293-26-000044 |
| 2026-02-04 | 08:48 ET | [8-K](/filings/0001824293-26-000040.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001824293-26-000040 |
| 2026-01-30 | 07:34 ET | [10-K](/filings/0001824293-26-000033.md) | Annual report, period 2025-12-31 | 0001824293-26-000033 |
| 2026-01-30 | 20:22 ET | [8-K](/filings/0001824293-26-000030.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001824293-26-000030 |
| 2026-01-28 | 08:46 ET | [8-K](/filings/0001824293-26-000017.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001824293-26-000017 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001824293-26-000033.md), filed Jan 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1824293
- Tickers: GRI
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.